SGS S.A.

SGS reported H1 sales of CHF 3.7 billion, up 7.6% in Swiss francs and 13.4% in constant currency, including 5.6% organic growth and 7.8% from M&A. Adjusted operating income margin was 15.1%, up 20 basis points, and EPS reached CHF 1.58, up 14.5% excluding the prior-year HQ disposal gain. Free cash flow was a record CHF 260 million, up 25% excluding HQ-sale proceeds. By segment, Industries & Environment grew 4.7% organically, Natural Resources 5.5%, Connectivity & Products 6.8%, Health & Nutrition 4.5%, and Business Assurance 7.3%. Management reaffirmed full-year guidance and said H2 should still benefit from momentum in North America, Digital Trust, Sustainability, ATS synergies, and bolt-on acquisitions, while Middle East disruption remains a headwind.

Geraldine Picaud emphasized execution of Strategy 27, with investment in Digital Trust, AI, Sustainability, ATS integration, and bolt-on acquisitions. She said SGS is seeing strong demand in areas tied to megatrends such as cyber resilience, AI assurance, energy transition, data centers, and food safety, and highlighted that the portfolio is designed to reduce earnings volatility. Her tone was confident and upbeat, stressing that the company is on track to meet guidance despite the Middle East situation.

Marta Vlatchkova focused on the record first half financials: CHF 3.7 billion of sales, 15.1% adjusted operating margin, CHF 260 million of free cash flow, and EPS of CHF 1.58. She broke down the margin bridge as CHF 39 million of organic improvement, CHF 42 million from M&A including ATS, and a CHF 35 million FX headwind from the strong Swiss franc. She also said restructuring costs were CHF 18 million in H1 and should be around CHF 30 million for the full year, and noted that financial expenses should not rise significantly in H2 despite higher net debt, helped by stronger cash generation.

Analysts focused on ATS margins and earnings contribution, balance-sheet working capital, restructuring costs, North America acceleration, Natural Resources momentum, free cash flow seasonality, and leverage. Management said ATS is on track, with EBITDA of about $98 million still the right reference, and that ATS is slightly above the group’s average margin and accretive overall. They said Middle East-related restructuring was about CHF 8 million in H1, North America improved on industrial testing, environmental testing, food, and pharma wins, and year-end leverage should be around 2.2x adjusted EBITDA, with a long-term preference to stay below 2x and ideally around 1.7x.